Investigational drug · Phase 3
Golidocitinib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for T-cell Lymphomas, Peripheral T-cell Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
40
Any phase or sponsor naming "Golidocitinib"
First trial start
2024
May 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Golidocitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- T-cell Lymphomas
- Peripheral T-cell Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Golidocitinib" as an intervention, largest first.
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07496229 · 220 participants (planned) · Start Apr 15, 2026 · Primary completion Sep 2029
Drug: GW5282 combined with Golidocitinib; GW5282 combined with Golidocitinib and 2 more · For: T-cell Lymphomas
Sites: Chongqing, China; Fuzhou, China; Nanning, China · 12 sites in all
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07234162 · 218 participants (planned) · Start May 13, 2024 · Primary completion Nov 30, 2027
Drug: Golidocitinib; Chidamide and 1 more · For: Peripheral T-cell Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 51 sites in all
- TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell LymphomaPivotal-lookingNot yet recruiting
Tarapeutics Science Inc.Industry
NCT07639879 · 180 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2029
Drug: TR115; Investigator's Choice · For: PTCL; NK T-Cell Lymphoma
Sites: Beijin, China
Dizal PharmaceuticalsIndustry
NCT04105010 · 171 participants · Start Sep 10, 2019 · Primary completion Oct 12, 2023
Drug: golidocitinib · For: Relapsed or Refractory Peripheral T Cell Lymphoma
Sites: New Haven, Connecticut; Atlanta, Georgia; St Louis, Missouri · 50 sites in all
- An Exploratory Study of Golidocitinib in Adult Patients With ITPPivotal-lookingNot yet recruiting
Peking University People's HospitalAcademic, hospital or other
NCT07196163 · 138 participants (planned) · Start Oct 30, 2025 · Primary completion Oct 30, 2028
Drug: Golidocitinib; Placebo · For: Immune Thrombocytopenia (ITP)
Sites: Beijing, China
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07300514 · 136 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 30, 2028
Drug: golidocitinib; Placebo · For: Maintenance Treatment of Peripheral T-cell Lymphoma
Sites: Shanghai, China
- New Genotype-guided Treatment in Newly Diagnosed PTCLPivotal-lookingNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT07706959 · 108 participants (planned) · Start Jul 2026 · Primary completion Jan 2028
Drug: Azacitidine plus Selinexor with CHOP; Decitabine plus Selinexor with CHOP and 3 more · For: Peripheral T-cell Lymphoma (PTCL)
Sites: Shanghai, China
Sun Yat-sen UniversityAcademic, hospital or other
NCT07093710 · 101 participants (planned) · Start Aug 27, 2025 · Primary completion Aug 1, 2027
Drug: Golidocitinib; Mitoxantrone Hydrochloride Liposome and 1 more · For: Peripheral T Cell Lymphoma
Sites: Guangzhou, China
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT07493330 · 86 participants (planned) · Start Mar 23, 2026 · Primary completion Dec 12, 2029
Drug: Zeprumetostat+Azacitadine; Zeprumetostat+Decitabine and 2 more · For: PTCL; Refractory
- Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06198907 · 69 participants (planned) · Start Jan 2024 · Primary completion Dec 2026
Drug: Golidocitinib; Sintilimab and 1 more · For: Non-Small-Cell Lung Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Golidocitinib ameliorates radio-immunotherapy-induced lung injury by alleviating oxidative stress and Pyroptosis.
Gao Z, Zhao Q, Li B, et al. · Int Immunopharmacol 2026
- The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.
Li M, Zhang Y, Li F, et al. · Pharmacol Res 2026
- Golidocitinib for Folliculotropic Mycosis Fungoides.
Zhang X, Chen Y, Xie Y, et al. · JAMA Dermatol 2026
- Golidocitinib as salvage therapy before allogeneic hematopoietic stem cell transplantation in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Li Y, Wang M, Shi L, et al. · Haematologica 2026
- Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma.
Wang B, Yu F, Wang Y, et al. · Front Oncol 2026
- SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.
Rana I, Zain J · Clin Lymphoma Myeloma Leuk 2026
Also in development for T-cell Lymphomas
- GW5282Phase 22 trials
Dizal Pharmaceuticals · T-cell Lymphomas, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.